Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

71,000

Sector

Pharmaceuticals

Calendar

16/12/2024 - Détachement de

More about the company

Quotes

Date	Price	Change	Volume
06/24/06	103.09 $	-0.44%	11,470,665
05/24/05	103.55 $	+2.15%	11,062,662
04/24/04	101.37 $	-0.47%	11,314,989
03/24/03	101.85 $	+1.23%	11,395,586
02/24/02	100.61 $	-1.01%	13,703,135

Delayed Quote Nyse, December 07, 2024 at 02:30 am IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart MERCK-CO-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

103.09USD

Average target price

130.33USD

Spread / Average Target

+26.42%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 02:30:34 07/12/2024 am IST			After market 06:25:49 am
103.09 ^USD	-0.44%		103.00	-0.09%

05/12	Merck: Phase III trial of Covid-19 begins	CF
05/12	Merck & Co., Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 08:00 AM

Capitalization	26TCr 25TCr 23TCr 20TCr 37TCr 22,08500Cr 41TCr 2,84600Cr 1,05200Cr 9,07400Cr 98TCr 96TCr 39,09700Cr	P/E ratio 2024 *	14.5x	P/E ratio 2025 *	11.9x
Enterprise value	28TCr 27TCr 25TCr 22TCr 40TCr 24,00800Cr 44TCr 3,09400Cr 1,14400Cr 9,86400Cr 1,06500Cr 1,04100Cr 42,50100Cr	EV / Sales 2024 *	4.43x	EV / Sales 2025 *	4x
Free-Float	70.72%	Yield 2024 *	2.96%	Yield 2025 *	3.1%

Merck: Phase III trial of Covid-19 begins	05/12	CF
Merck & Co., Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 08:00 AM	05/12
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults	05/12	MT
Merck & Co., Inc. Announces Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOTM (Molnupiravir) for the Treatment of Covid-19 in High-Risk Adults	05/12	CI
From Fed foresight to French fears	04/12
Analyst recommendations: Merck, Salesforce, Block, Lyft, Bunzl...	04/12
HSBC Upgrades Merck to Buy, Price Target at $130	04/12	MT
Merck & Co., Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-03-2024 01:20 PM	03/12
Merck: 'therapeutic breakthrough' for antibody-conjugate	03/12	CF
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation	03/12	MT
Merck's Sacituzumab Tirumotecan Granted FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC	03/12	CI
Bernstein Trims Price Target on Merck to $110 From $115	02/12	MT
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	29/11	MT

Analyst recommendations: Merck, Salesforce, Block, Lyft, Bunzl...	04/12
HSBC Upgrades Merck to Buy, Price Target at $130	04/12	MT
Bernstein Trims Price Target on Merck to $110 From $115	02/12	MT
Jefferies Raises Merck Price Target to $150 From $149, Buy Rating Maintained	25/11	MT
Jefferies Adjusts Price Target on Merck to $149 From $148, Maintains Buy Rating	22/11	MT

Merck & Co., Inc. Share Price

Equities

MRK

US58933Y1055

Pharmaceuticals

Valuation: Merck & Co., Inc.

Chart: Merck & Co., Inc.

Latest news: Merck & Co., Inc.

Last Transcript: Merck & Co., Inc.

Analysts' recommendations: Merck & Co., Inc.

Press Releases: Merck & Co., Inc.

News in other languages: Merck & Co., Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Merck & Co., Inc.

ETFs: Merck & Co., Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Merck : Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025	05/12	PU
Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025	05/12	AQ
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults	05/12	BU
Cyber Insurance Update: Recent Decisions Addressing Coverage For Cyber Losses	04/12	AQ
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations	03/12	BU

Merck : démarrage d'un essai de phase III dans le Covid-19	05/12
Merck : 'percée thérapeutique' pour un anticorps-conjugué	03/12
Merck : succès d'une étude dans l'hypertension artérielle	25/11
Merck : le DG d'Emerson Electric va rejoindre le conseil	22/11
Merck : feu vert pour Welireg en Chine dans la maladie de VHL	22/11

1 day	-0.09%
1 week	+1.43%
Current month	+1.43%
1 month	+2.34%
3 months	-12.52%
6 months	-21.02%
Current year	-5.44%

Director	Title	Age	Since
Robert Davis CEO	Chief Executive Officer	57	01/07/2021
Caroline Litchfield DFI	Director of Finance/CFO	55	01/04/2021
Dave Williams CTO	Chief Tech/Sci/R&D Officer	55	01/08/2020

Manager	Title	Age	Since
Tom Glocer BRD	Director/Board Member	64	27/11/2007
Patricia Russo BRD	Director/Board Member	71	01/09/1995
Robert Davis CHM	Chairman	57	01/12/2022

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	14.34%	380 M€	+9.14%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	5.61%	20 M€	+16.75%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
MERCK & CO., INC.	-0.44%	+1.43%	-2.40%	+40.41%	26TCr
ELI LILLY AND COMPANY	+0.13%	+3.94%	+40.30%	+235.61%	74TCr
NOVO NORDISK A/S	+1.88%	+3.72%	+15.77%	+121.70%	49TCr
JOHNSON & JOHNSON	-0.14%	-3.68%	-4.67%	-8.37%	36TCr
ABBVIE INC.	+0.01%	-3.68%	+20.36%	+45.19%	31TCr
ROCHE HOLDING AG	+0.27%	+0.59%	+2.82%	-30.08%	24TCr
ASTRAZENECA PLC	+0.34%	+0.40%	+5.17%	+27.39%	21TCr
NOVARTIS AG	-0.63%	-3.71%	+5.80%	+20.34%	20TCr
AMGEN INC.	-0.64%	-3.64%	+1.20%	+30.55%	15TCr
PFIZER, INC.	+0.12%	-1.83%	-10.63%	-50.02%	15TCr
Average	+0.21%	-0.49%	+7.37%	+43.27%	31.12TCr
Weighted average by Cap.	+0.38%	+0.50%	+13.94%	+82.59%

	2024 *	2025 *
Net sales	6.4TCr 6.06TCr 5.62TCr 5.02TCr 9.05TCr 5,42100Cr 10TCr 70TCr 26TCr 2,22800Cr 24TCr 24TCr 9,59800Cr	6.75TCr 6.39TCr 5.92TCr 5.3TCr 9.55TCr 5,71900Cr 11TCr 74TCr 27TCr 2,35000Cr 25TCr 25TCr 10,12400Cr
Net income	1.78TCr 1.68TCr 1.56TCr 1.4TCr 2.51TCr 1,50600Cr 2.78TCr 19TCr 7.18TCr 62TCr 6.68TCr 6.53TCr 2,66700Cr	2.22TCr 2.1TCr 1.94TCr 1.74TCr 3.13TCr 1,87700Cr 3.47TCr 24TCr 8.95TCr 77TCr 8.33TCr 8.14TCr 3,32300Cr
Net Debt	2.27TCr 2.15TCr 1.99TCr 1.78TCr 3.21TCr 1,92300Cr 3.55TCr 25TCr 9.16TCr 79TCr 8.53TCr 8.34TCr 3,40400Cr	947.46Cr 896.58Cr 831.14Cr 743.3Cr 1.34TCr 80TCr 1.48TCr 10TCr 3.82TCr 33TCr 3.56TCr 3.48TCr 1,42000Cr